Today, preparations are being made to
begin phase IIa human trials on this promising compound as a single - dose cure.
Not exact matches
Novavax says that during
Phase IIa of seasonal flu vaccine testing, which
began in May, it was able in the majority of people tested to surpass the FDA's requirements for producing enough antibodies to protect the body from the H3N2, H1N1 and B viruses — all of which were common enough a year ago to be used to develop flu vaccines for the 2008 to 2009 flu season.
deCODE genetics (Nasdaq: DCGN) today announced that it has
begun enrolling patients for its
Phase IIa clinical trial for DG051, the company's leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack.